DOPAMINE AGONISTS AND METOCLOPRAMIDE

Centrally-acting dopamine antagonists (such as metoclopramide) are expected to oppose the effects of the dopamine agonists. Metoclopramide would also be expected to reduce the prolactin-lowering effect of bromocriptine.
Concurrent use should be avoided, or monitored closely to ensure that the dopamine agonist remains effective. Domperidone is the antiemetic of choice in Parkinson's disease.